No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak
→ When Mythic Therapeutics CEO Alex Nichols spoke to Endpoints News last December about the biotech’s $103 million Series B, he and fellow co …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
